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grade improvement in the MR grade prior to discharge. Despite
this improvement, 30 day and 1 year mortality is signiﬁcantly
higher in those with moderate or severe MR than those with minimal
MR.None
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BACKGROUND Clopidogrel nonresponsiveness is a strong marker of
the risk of cardiac death and stent thrombosis after percutaneous
coronary intervention (PCI). It is unknown if clopidogrel non-
resposiveness is a nonmodiﬁable risk factor or if prasugrel with more
potent and predictable platelet inhibition as measured by ex vivo
techniques is associated with a positive effect on clinical outcome.
This study sought to investigate the efﬁcacy of prasugrel as compared
with clopidogrel in clopidogrel nonresponders.
METHODS REsponsiveness to CLOpidogrel and StEnt thrombosis
(RECLOSE)- 3 study screened clopidogrel nonresponders after a 600
mg loading dose of clopidogrel. Clopidogrel nonresponders switched
to prasugrel (10 mg/daily) the day of PCI, and ADP test (10 mmo/L of
ADP ) performed 6 days after PCI. The primary end point was 2-year
cardiac mortality. Patient outcome was compared with the RECLOSE-2
study.
RESULTS We screened 1,550 patients, and 302 were clopidogrel
nonresponders. The ADP test was 77.6  6.2%. After switching to
prasugrel the ADP test result was reduced to 47.1  16.8%. The 2-
year cardiac mortality rate was 4% in the RECLOSE-3 study and 9.7
% in nonresponders of the RECLOSE-2 study (p ¼ 0.007). The deﬁ-
nite/probable stent thrombosis rates were 0.7% and 4.4%, respec-
tively (p ¼ 0.004). At the ﬁnal multivariable analysis, prasugrel
treatment was related to the risk of 2-year cardiac death (HR 0.32,
p¼0.036) after adjusting for age, ACS and renal insufﬁciency.CONCLUSIONS Clopidogrel nonresponsiveness can be overcame by
prasugrel (10 mg/daily), and optimal platelet aggregation inhibition on
prasugrel treatment is associated with a low rate of long-term cardiac
mortality and stent thrombosis.
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